A safety evaluation of canagliflozin : a first-in-class treatment for type 2 diabetes
Luke D Boyle1, John P H Wilding
1University of Liverpool, University Hospital Aintree, Clinical Sciences Centre, Department of Obesity and Endocrinology , 3rd floor, CSC, Longmoor Lane, Liverpool, L9 7AL , UK +44 151 529 5885 ; +44 151 529 5888 ; j.p.h.wilding@liv.ac.uk.
Introduction:
Numerous treatments are available for type 2 diabetes mellitus (T2DM), which can improve insulin sensitivity or stimulate its secretion. These are usually unable to halt progression. Inhibition of glucose reabsorption from the renal filtrate was proposed as a novel therapeutic target. Sodium/glucose co-transporter 2 (SGLT2) inhibitors were developed accordingly, with canagliflozin the first to launch in the US in 2013.
Areas Covered:
The mechanism of action of canagliflozin, its pharmacokinetic data and its clinical applications and efficacy data from clinical studies of both subjects with T2DM controlled on diet and exercise, and those on glucose-lowering agents and insulin. The evaluation focuses primarily on the safety of canagliflozin in clinical trials conducted for initial registration due to limited post-marketing data, discusses safety in special populations, before comparing its safety with existing therapies.
Expert Opinion:
Canagliflozin offers a novel therapeutic approach to T2DM; advantages include weight loss and blood pressure lowering with a low intrinsic risk of hypoglycaemia. The main adverse effects likely to be seen are a very small increase in risk of urinary tract infections and a modest risk of developing genital fungal infections. Studies suggest no increased risk of cardiovascular (CV) disease, but longer duration outcome studies are essential.
Insights
Canagliflozin, a novel sodium/glucose co-transporter 2 (SGLT2) inhibitor, offers a new treatment for type 2 diabetes mellitus (T2DM) with benefits like weight loss and blood pressure reduction.
Area of Science:
- Endocrinology
- Pharmacology
- Nephrology
Background:
- Type 2 diabetes mellitus (T2DM) treatments often fail to halt disease progression.
- Inhibiting renal glucose reabsorption presents a novel therapeutic strategy.
- Sodium/glucose co-transporter 2 (SGLT2) inhibitors, like canagliflozin, emerged from this strategy.
Purpose of the Study:
- To review the mechanism of action, pharmacokinetics, and clinical efficacy of canagliflozin.
- To evaluate the safety profile of canagliflozin based on initial clinical trials.
- To compare canagliflozin's safety with existing T2DM therapies.
Main Methods:
- Review of canagliflozin's mechanism of action and pharmacokinetic data.
- Analysis of clinical trial data for efficacy in T2DM patients.
- Primary focus on safety data from initial registration trials and special populations.
Main Results:
- Canagliflozin demonstrates efficacy in managing T2DM, offering weight loss and blood pressure reduction.
- Low intrinsic risk of hypoglycemia is a key advantage.
- Potential adverse effects include increased risk of urinary tract and genital fungal infections.
Conclusions:
- Canagliflozin represents a novel therapeutic option for T2DM.
- Cardiovascular benefits are suggested but require further long-term outcome studies.
- Ongoing research is essential to fully understand long-term safety and efficacy.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
01:24Type II Diabetes II: Pathophysiology
01:26Type II Diabetes I: Introduction
01:15Diabetes: Symptoms, Diagnosis, and Complications
01:22Diabetes Mellitus: Type 2 and Gestational